LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics (Nasdaq: LENZ), a pre-commercial stage biopharmaceutical company developing aceclidine-based eye drops for presbyopia, has announced its participation in four major investor conferences in November and December 2024.
The company will attend the Jefferies London Healthcare Conference (Nov 19-21), Piper Sandler Healthcare Conference (Dec 3, 3:30pm ET), Evercore HealthCONx Conference (Dec 4, 7:30 AM ET), and Citi Global Healthcare Conference (Dec 5, 1:45 PM ET). Management will participate in one-on-one meetings at all events and deliver presentations at three conferences.
A live webcast of the Piper Sandler fireside chat will be available on the company's website for 12 months.
LENZ Therapeutics (Nasdaq: LENZ), un'azienda biofarmaceutica in fase pre-commerciale che sviluppa colliri a base di aceclidina per la presbiopia, ha annunciato la sua partecipazione a quattro importanti conferenze per investitori a novembre e dicembre 2024.
L'azienda parteciperà alla Jefferies London Healthcare Conference (19-21 novembre), alla Piper Sandler Healthcare Conference (3 dicembre, 15:30 ET), all'Evercore HealthCONx Conference (4 dicembre, 7:30 AM ET) e alla Citi Global Healthcare Conference (5 dicembre, 13:45 PM ET). La direzione parteciperà a incontri individuali in tutti gli eventi e presenterà interventi in tre conferenze.
Una diretta web del colloquio informale di Piper Sandler sarà disponibile sul sito web dell'azienda per 12 mesi.
LENZ Therapeutics (Nasdaq: LENZ), una compañía biofarmacéutica en etapa precomercial que está desarrollando gotas oftálmicas a base de aceclidina para la presbicia, ha anunciado su participación en cuatro importantes conferencias para inversores en noviembre y diciembre de 2024.
La compañía asistirá a la Jefferies London Healthcare Conference (19-21 de noviembre), a la Piper Sandler Healthcare Conference (3 de diciembre, 15:30 ET), a la Evercore HealthCONx Conference (4 de diciembre, 7:30 AM ET) y a la Citi Global Healthcare Conference (5 de diciembre, 13:45 PM ET). La dirección participará en reuniones uno a uno en todos los eventos y dará presentaciones en tres conferencias.
Una transmisión en vivo de la charla de Piper Sandler estará disponible en el sitio web de la compañía durante 12 meses.
LENZ Therapeutics (Nasdaq: LENZ)는 노안 치료를 위한 아세클리딘 기반 점안액을 개발하는 상업화 전 단계의 생명과학 기업으로, 2024년 11월과 12월에 열리는 네 개의 주요 투자자 회의에 참여할 예정이라고 발표했습니다.
회사는 제퍼리즈 런던 헬스케어 컨퍼런스 (11월 19-21일), 파이퍼 샌들러 헬스케어 컨퍼런스 (12월 3일, 오후 3시 30분 ET), 에버코어 헬스콘엑스 컨퍼런스 (12월 4일, 오전 7시 30분 ET), 시티 글로벌 헬스케어 컨퍼런스 (12월 5일, 오후 1시 45분 ET)에 참석할 예정입니다. 경영진은 모든 이벤트에서 일대일 미팅에 참여하고 세 개의 컨퍼런스에서 발표를 진행할 것입니다.
파이퍼 샌들러의 파이어사이드 챗의 생중계는 회사 웹사이트에서 12개월 동안 이용 가능합니다.
LENZ Therapeutics (Nasdaq: LENZ), une entreprise biopharmaceutique en phase pré-commerciale développant des gouttes oculaires à base d'aceclidine pour la presbytie, a annoncé sa participation à quatre grandes conférences pour investisseurs en novembre et décembre 2024.
La société participera à la Jefferies London Healthcare Conference (19-21 novembre), à la Piper Sandler Healthcare Conference (3 décembre, 15h30 ET), à la Evercore HealthCONx Conference (4 décembre, 7h30 ET) et à la Citi Global Healthcare Conference (5 décembre, 13h45 ET). La direction participera à des réunions individuelles lors de tous les événements et fera des présentations lors de trois conférences.
Une diffusion en direct de la discussion informelle de Piper Sandler sera disponible sur le site web de l'entreprise pendant 12 mois.
LENZ Therapeutics (Nasdaq: LENZ), ein biopharmazeutisches Unternehmen in der präkommerziellen Phase, das aceclidinbasierte Augentropfen zur Behandlung von Presbyopie entwickelt, hat seine Teilnahme an vier wichtigen Investorenkonferenzen im November und Dezember 2024 bekannt gegeben.
Das Unternehmen wird an der Jefferies London Healthcare Conference (19.-21. November), der Piper Sandler Healthcare Conference (3. Dezember, 15:30 Uhr ET), der Evercore HealthCONx Conference (4. Dezember, 7:30 Uhr ET) und der Citi Global Healthcare Conference (5. Dezember, 13:45 Uhr ET) teilnehmen. Die Geschäftsleitung wird an Einzelgesprächen bei allen Veranstaltungen teilnehmen und wird auf drei Konferenzen Präsentationen halten.
Ein Live-Stream des Piper Sandler Feuergesprächs wird für 12 Monate auf der Website des Unternehmens verfügbar sein.
- None.
- None.
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
Jefferies London Healthcare Conference (London, UK)
Management will participate in one-on-one meetings from Tuesday, November 19th through Thursday, November 21st, 2024.
Piper Sandler 36th Annual Healthcare Conference (New York, NY)
Management is scheduled to participate in a fireside chat on Tuesday, December 3rd, 2024 at 3:30pm ET and will participate in one-on-one meetings.
7th Annual Evercore HealthCONx Conference (Coral Gables, FL)
Management is scheduled to participate in a fireside chat on Wednesday, December 4th, 2024 at 7:30 AM ET and will participate in one-on-one meetings.
Citi 2024 Global Healthcare Conference (Miami, FL)
Management is scheduled to participate in a panel discussion titled, “Eyes Wide Open on Ophthalmology” on Thursday, December 5, 2024 at 1:45 PM ET and will participate in one-on-one meetings.
A live audio webcast of the Piper Sandler Healthcare Conference fireside chat can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 12 months following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
What investor conferences will LENZ Therapeutics (LENZ) attend in November-December 2024?
When is LENZ Therapeutics' presentation at the Piper Sandler Healthcare Conference 2024?
What is LENZ Therapeutics' main product in development?
Will LENZ Therapeutics' conference presentations be available online?
